Literature DB >> 27411401

Diabetes: Time for reconciliation between cardiologists and diabetologists.

André J Scheen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27411401     DOI： 10.1038/nrcardio.2016.113

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.

Authors:  André J Scheen
Journal:  Diabetes Metab       Date:  2016-02-05       Impact factor: 6.041

Review 2.  Cardiovascular effects of gliptins.

Authors:  André J Scheen
Journal:  Nat Rev Cardiol       Date:  2013-01-08       Impact factor: 32.419

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 4.  Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal.

Authors:  A J Scheen; B Charbonnel
Journal:  Diabetes Metab       Date:  2014-04-30       Impact factor: 6.041

5.  Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

Authors:  Ele Ferrannini; Simona Baldi; Silvia Frascerra; Brenno Astiarraga; Tim Heise; Roberto Bizzotto; Andrea Mari; Thomas R Pieber; Elza Muscelli
Journal:  Diabetes       Date:  2016-02-09       Impact factor: 9.461

Review 6.  Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

7.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

8.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Authors:  Marc A Pfeffer; Brian Claggett; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Lars V Køber; Francesca C Lawson; Lin Ping; Xiaodan Wei; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Authors:  David Fitchett; Bernard Zinman; Christoph Wanner; John M Lachin; Stefan Hantel; Afshin Salsali; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  Eur Heart J       Date:  2016-01-26       Impact factor: 29.983
  10 in total
  4 in total

Review 1.  Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review.

Authors:  Salvatore Carbone; Dave L Dixon; Leo F Buckley; Antonio Abbate
Journal:  Mayo Clin Proc       Date:  2018-11       Impact factor: 7.616

Review 2.  Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

3.  Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).

Authors:  Guntram Schernthaner; Kamlesh Khunti; Chaim Lotan; Michel Burnier; Heinz Drexel; Martin Prázný
Journal:  Ther Clin Risk Manag       Date:  2017-12-13       Impact factor: 2.423

Review 4.  Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.

Authors:  André J Scheen
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.